Pfizer Financial Statements (PFE)
|
|
|
|
Report date
|
|
|
24.02.2022 |
23.02.2023 |
22.02.2024 |
27.02.2025 |
26.02.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
81 288 |
100 330 |
59 553 |
63 627 |
62 579 |
|
63 315 |
|
Operating Income, bln rub |
|
|
20 793 |
37 549 |
5 292 |
16 483 |
15 437 |
|
14 845 |
|
EBITDA, bln rub |
? |
|
30 793 |
41 031 |
9 557 |
18 127 |
15 096 |
|
16 942 |
|
Net profit, bln rub |
? |
|
22 147 |
31 365 |
2 133 |
8 020 |
7 770 |
|
7 491 |
|
|
OCF, bln rub |
? |
|
32 580 |
29 267 |
8 700 |
12 744 |
11 705 |
|
11 985 |
|
CAPEX, bln rub |
? |
|
2 711 |
3 236 |
3 907 |
2 909 |
2 629 |
|
2 501 |
|
FCF, bln rub |
? |
|
29 869 |
26 031 |
4 793 |
9 835 |
9 076 |
|
9 484 |
|
Dividend payout, bln rub
|
|
|
8 729 |
8 983 |
9 247 |
9 512 |
9 771 |
|
9 779 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
39.4% |
28.6% |
433.5% |
118.6% |
125.8% |
|
130.5% |
|
|
OPEX, bln rub |
|
|
26 082 |
24 541 |
25 048 |
25 363 |
28 577 |
|
29 062 |
|
Cost of production, bln rub |
|
|
34 413 |
38 240 |
29 213 |
21 781 |
18 565 |
|
19 408 |
|
R&D, bln rub |
|
|
13 828 |
11 426 |
10 578 |
10 738 |
11 976 |
|
12 424 |
|
Interest expenses, bln rub |
|
|
1 291 |
1 238 |
2 209 |
3 091 |
2 671 |
|
2 685 |
|
|
Assets, bln rub |
|
|
181 477 |
197 206 |
226 501 |
213 396 |
208 160 |
|
207 618 |
|
Net Assets, bln rub |
? |
|
77 201 |
95 661 |
89 014 |
88 203 |
86 476 |
|
90 101 |
|
Debt, bln rub |
|
|
36 998 |
34 859 |
70 845 |
66 993 |
67 416 |
|
64 455 |
|
Cash, bln rub |
|
|
31 069 |
22 732 |
12 690 |
20 477 |
13 596 |
|
13 075 |
|
Net debt, bln rub |
|
|
5 929 |
12 127 |
58 155 |
46 516 |
53 820 |
|
51 380 |
|
|
Ordinary share price, rub |
|
|
59.1 |
|
|
26.5 |
24.9 |
|
25.9 |
|
Number of ordinary shares, mln |
|
|
5 601 |
5 608 |
5 643 |
5 664 |
5 683 |
|
5 691 |
|
|
Market cap, bln rub |
|
|
330 739 |
0 |
0 |
150 266 |
141 501 |
|
147 397 |
|
EV, bln rub |
? |
|
336 668 |
12 127 |
58 155 |
196 782 |
195 321 |
|
198 777 |
|
Book value, bln rub |
|
|
2 847 |
916 |
-43 669 |
-35 736 |
-38 519 |
|
-33 867 |
|
|
EPS, rub |
? |
|
3.95 |
5.59 |
0.38 |
1.42 |
1.37 |
|
1.32 |
|
FCF/share, rub |
|
|
5.33 |
4.64 |
0.85 |
1.74 |
1.60 |
|
1.67 |
|
BV/share, rub |
|
|
0.51 |
0.16 |
-7.74 |
-6.31 |
-6.78 |
|
-5.95 |
|
|
EBITDA margin, % |
? |
|
37.9% |
40.9% |
16.0% |
28.5% |
24.1% |
|
26.8% |
|
Net margin, % |
? |
|
27.2% |
31.3% |
3.58% |
12.6% |
12.4% |
|
11.8% |
|
FCF yield, % |
? |
|
9.03% |
|
|
6.55% |
6.41% |
|
6.43% |
|
ROE, % |
? |
|
28.7% |
32.8% |
2.40% |
9.09% |
8.99% |
|
8.31% |
|
ROA, % |
? |
|
12.2% |
15.9% |
0.94% |
3.76% |
3.73% |
|
3.61% |
|
|
P/E |
? |
|
14.9 |
0.00 |
0.00 |
18.7 |
18.2 |
|
19.7 |
|
P/FCF |
|
|
11.1 |
0.00 |
0.00 |
15.3 |
15.6 |
|
15.5 |
|
P/S |
? |
|
4.07 |
0.00 |
0.00 |
2.36 |
2.26 |
|
2.33 |
|
P/BV |
? |
|
116.2 |
0.00 |
0.00 |
-4.20 |
-3.67 |
|
-4.35 |
|
EV/EBITDA |
? |
|
10.9 |
0.30 |
6.09 |
10.9 |
12.9 |
|
11.7 |
|
Debt/EBITDA |
|
|
0.19 |
0.30 |
6.09 |
2.57 |
3.57 |
|
3.03 |
|
|
R&D/CAPEX, % |
|
|
510.1% |
353.1% |
270.7% |
369.1% |
455.5% |
|
496.8% |
|
|
CAPEX/Revenue, % |
|
|
3.34% |
3.23% |
6.56% |
4.57% |
4.20% |
|
3.95% |
|
| Pfizer shareholders |
